NCT04208620View on ClinicalTrials.gov

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions

Type 2 Diabetes

Interventions

DRUG

Placebo

Placebo administered subcutaneously

DRUG

Cotadutide

Cotadutide administered subcutaneously

Trial Locations (3)

160-0008

Research Site, Shinjuku-ku

162-0053

Research Site, Shinjuku-ku

565-0853

Research Site, Suita-shi

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

MedImmune LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY